Updated:
Pasithea Therapeutics
Pasithea Therapeutics was established in 2020 by Dr. Tiago Reis Marques, a psychiatrist and lecturer at King's College London. The firm went public on the...
Pasithea Therapeutics
Pasithea Therapeutics was established in 2020 by Dr. Tiago Reis Marques, a psychiatrist and lecturer at King's College London. The firm went public on the Nasdaq in 2021 and maintains a dual structure: a clinical-stage drug development program focused on repurposing approved therapies for psychiatric and neurological disorders, alongside a wholly owned network of ketamine infusion clinics operating under the Pasithea Clinics brand in the United Kingdom and the United States. The drug development pipeline centers on PAS-004, a next-generation macrocyclic MEK inhibitor licensed from Allinky Biopharma, for which the firm dosed its first patient in a Phase 1 clinical trial in 2024 (per the firm's SEC filings, 2024). The broader strategy targets neurofibromatosis type 1, ALS, and other conditions with limited treatment options. The clinic division provides intravenous ketamine therapy for treatment-resistant depression and other mood disorders, generating operational revenue while the drug pipeline matures. This hybrid operating model — pairing a clinical services cash engine with a capital-intensive drug development program — is unusual for a micro-cap biotech. Pasithea operates from Miami Beach, Florida, with its clinic footprint concentrated in the U.K. market, where it acquired multiple locations including a former Zappy Clinic site. The firm has historically maintained a lean public-company structure with minimal institutional analyst coverage. In May 2024, Pasithea announced the dosing of the first healthy volunteer in its Phase 1 trial of PAS-004, the company's lead oncology and neurology asset (per the firm, May 2024). What structurally differentiates Pasithea is its cash-generating clinic subsidiary. The ketamine infusion business is not just a side project — it is the revenue backbone that partially funds R&D. For a pre-revenue biotech, this clinic-tethered model reduces the frequency of dilutive capital raises, though the firm remains dependent on equity markets to fund its clinical trials. The succession of leadership remains concentrated in Reis Marques, who serves as CEO and chairman.
General information
Firm type
Asset Manager
Year founded
2020
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Miami Beach
Corporate office
Miami Beach, FL, United States
Principals
Tiago Reis Marques
Chief Executive Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Pasithea Therapeutics?
Pasithea is not a fund but a publicly traded biotech company led by founder and CEO Dr. Tiago Reis Marques. Capital allocation decisions — including clinic acquisitions and clinical trial funding — are made by the executive leadership team and board of directors. The firm's SEC filings are the primary source for understanding its use of proceeds.
Is Pasithea Therapeutics structured as a single family office or does it operate more like a venture firm?
Neither. Pasithea Therapeutics Corp. is a clinical-stage biotechnology company listed on the Nasdaq under the ticker KTTA. It does not manage third-party capital or operate as a family office. Its corporate structure includes a wholly owned subsidiary, Pasithea Clinics, which provides ketamine infusion therapy.
Does Pasithea participate in fund commitments or only direct deals?
Pasithea is an operating company, not an allocator. It has historically made direct acquisitions of ketamine clinics in the U.K. to expand its clinic network, such as the purchase of a former Zappy Clinic site. The firm does not make fund commitments to external managers.
What investment stages does Pasithea typically target?
Pasithea does not invest in external companies. On the drug development side, the firm in-licenses clinical-stage or preclinical assets, such as PAS-004 from Allinky Biopharma, and advances them through internal trials. Its clinic division acquires existing ketamine infusion practices.
Which sectors does Pasithea explicitly avoid?
Pasithea's public disclosures focus exclusively on neuropsychiatry, neurology, and oncology — specifically drug repurposing and ketamine therapy. The firm has not signaled interest in immunology, metabolic disease, or other divergent therapeutic areas.
How is Pasithea related to its ketamine clinics?
Pasithea Clinics is a wholly owned subsidiary of Pasithea Therapeutics Corp. The clinics generate revenue through intravenous ketamine infusions for treatment-resistant depression, while the parent company uses that income to offset R&D spending. This structure distinguishes Pasithea from pure-play biotechs that lack a commercial revenue stream.
Does Pasithea maintain philanthropic structures, and how are they separated?
There is no public record of a philanthropic foundation or donor-advised fund tied to Pasithea Therapeutics or its founder. Dr. Reis Marques has published extensively in psychiatric journals and lectures at King's College London, but his academic and corporate work do not appear to be routed through a charitable vehicle.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: